Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. operates in the regenerative medicine sector, focusing on advanced wound care, surgical, and sports medicine markets, with a diverse portfolio of established products that positions the company favorably in its industry. Despite mixed performance due to market dynamics and reimbursement changes, there is optimism for improved valuation as the company generates solid results, indicating potential for share appreciation in the future. Furthermore, a recent uptick in reimbursement rates and a continued focus on capturing market share amidst consolidation provide a solid foundation for sustained operating profit growth, corroborating a positive outlook for the company.

Bears say

Organogenesis Holdings Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include the potential for lower-than-expected growth in the PuraPly product line, pricing pressures from Medicare Part B on amniotic products, and competitive disadvantages related to regulatory integration that may hinder market share gains. Additionally, the company may struggle with the uptake of new products, adverse clinical data outcomes, and the implications of reduced sales force structures which could compress commissions and overall revenue potential.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.